Announcement of Availability of Inavolisib

April 07, 2023

The Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using inavolisib, a p110α isoform-selective inhibitor that promotes the specific degradation of mutated p110α, which is being developed by CTEP as an anticancer agent in collaboration with Genentech, Inc. CTEP will also consider requests to supply inavolisib for nonclinical studies. All clinical and nonclinical researchers possessing an interest in working with the agent are welcome to apply. Proposals for clinical trials should be supported by a strong rationale and robust preclinical data (see “Components of a Competitive Letter of Intent” at http://ctep.cancer.gov/protocolDevelopment/lois_concepts.htm).

All proposals approved by CTEP will be sent to the industry collaborator for a commitment to supply drug for the study.

Questions may be addressed to Rabih Said, M.D., M.P.H., Medical Officer, Investigational Drug Branch, CTEP, DCTD, NCI (phone: 240-276-6565; FAX: 240-276-7894; e-mail: rabih.said@mail.nih.gov).

If you are a DFHCC Investigator interested in submitting an LOI using Inavolisib through the ETCTN, please contact Dr. Geoff Shapiro (geoffrey_shapiro@dfci.harvard.edu)

For more information please see the related documents below